{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:23:46Z","timestamp":1790663026943,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI098302"],"award-info":[{"award-number":["R01AI098302"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI098302"],"award-info":[{"award-number":["R01AI098302"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI098302"],"award-info":[{"award-number":["R01AI098302"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malaria remains a major cause of morbidity and mortality worldwide with 219 million infections and 435,000 deaths predominantly in Africa. The infective<jats:italic>Plasmodium<\/jats:italic>sporozoite is the target of a potent humoral immune response that can protect murine, simian and human hosts against challenge by malaria-infected mosquitoes. Early murine studies demonstrated that sporozoites or subunit vaccines based on the sporozoite major surface antigen, the circumsporozoite (CS) protein, elicit antibodies that primarily target the central repeat region of the CS protein. In the current murine studies, using monoclonal antibodies and polyclonal sera obtained following immunization with<jats:italic>P. falciparum<\/jats:italic>sporozoites or synthetic repeat peptides, we demonstrate differences in the ability of these antibodies to recognize the major and minor repeats contained in the central repeat region. The biological relevance of these differences in fine specificity was explored using a transgenic<jats:italic>P. berghei<\/jats:italic>rodent parasite expressing the<jats:italic>P. falciparum<\/jats:italic>CS repeat region. In these in vitro and in vivo studies, we demonstrate that the minor repeat region, comprised of three copies of alternating NANP and NVDP tetramer repeats, contains an epitope recognized by sporozoite-neutralizing antibodies. In contrast, murine monoclonal antibodies specific for the major CS repeats (NANP)<jats:sub>n<\/jats:sub>could be isolated from peptide-immunized mice that had limited or no sporozoite-neutralizing activity. These studies highlight the importance of assessing the fine specificity and functions of antirepeat antibodies elicited by<jats:italic>P. falciparum<\/jats:italic>CS-based vaccines and suggest that the design of immunogens to increase antibody responses to minor CS repeats may enhance vaccine efficacy.<\/jats:p>","DOI":"10.1038\/s41541-020-00272-6","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T11:17:06Z","timestamp":1610968626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Identification of a neutralizing epitope within minor repeat region of Plasmodium falciparum CS protein"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-2336","authenticated-orcid":false,"given":"J. Mauricio","family":"Calvo-Calle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0424-7257","authenticated-orcid":false,"given":"Robert","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Altszuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Othoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Nardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"272_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0769-2625(85)80115-X","volume":"136D","author":"V Nussenzweig","year":"1985","unstructured":"Nussenzweig, V. & Nussenzweig, R. S. Malaria vaccine against sporozoites? Ann. Inst. Pasteur Immunol. 136D, 301\u2013312 (1985).","journal-title":"Ann. Inst. Pasteur Immunol."},{"key":"272_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0065-2776(08)60695-1","volume":"45","author":"V Nussenzweig","year":"1989","unstructured":"Nussenzweig, V. & Nussenzweig, R. S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 45, 283\u2013334 (1989).","journal-title":"Adv. Immunol."},{"key":"272_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1128\/IAI.51.3.859-864.1986","volume":"51","author":"MJ Stewart","year":"1986","unstructured":"Stewart, M. J., Nawrot, R. J., Schulman, S. & Vanderberg, J. P. Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infect. Immun. 51, 859\u2013864 (1986).","journal-title":"Infect. Immun."},{"key":"272_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.ijpara.2004.05.005","volume":"34","author":"JP Vanderberg","year":"2004","unstructured":"Vanderberg, J. P. & Frevert, U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int. J. Parasitol. 34, 991\u2013996 (2004).","journal-title":"Int. J. Parasitol."},{"key":"272_CR5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.4049\/jimmunol.128.4.1929","volume":"128","author":"MR Hollingdale","year":"1982","unstructured":"Hollingdale, M. R., Zavala, F., Nussenzweig, R. S. & Nussenzweig, V. Antibodies to the protective antigen of Plasmodium berghei sporozoites prevent entry into cultured cells. J. Immunol. 128, 1929\u20131930 (1982).","journal-title":"J. Immunol."},{"key":"272_CR6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4049\/jimmunol.132.2.909","volume":"132","author":"MR Hollingdale","year":"1984","unstructured":"Hollingdale, M. R., Nardin, E. H., Tharavanij, S., Schwartz, A. L. & Nussenzweig, R. S. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J. Immunol. 132, 909\u2013913 (1984).","journal-title":"J. Immunol."},{"key":"272_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1126\/science.1704150","volume":"251","author":"Y Charoenvit","year":"1991","unstructured":"Charoenvit, Y. et al. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science 251, 668\u2013671 (1991).","journal-title":"Science"},{"key":"272_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1172\/JCI70349","volume":"124","author":"L Foquet","year":"2014","unstructured":"Foquet, L. et al. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J. Clin. Invest. 124, 140\u2013144 (2014).","journal-title":"J. Clin. Invest."},{"key":"272_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1126\/science.6204383","volume":"225","author":"JB Dame","year":"1984","unstructured":"Dame, J. B. et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225, 593\u2013599 (1984).","journal-title":"Science"},{"key":"272_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1084\/jem.20040989","volume":"201","author":"A Coppi","year":"2005","unstructured":"Coppi, A., Pinzon-Ortiz, C., Hutter, C. & Sinnis, P. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J. Exp. Med. 201, 27\u201333 (2005).","journal-title":"J. Exp. Med."},{"key":"272_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1084\/jem.20101488","volume":"208","author":"A Coppi","year":"2011","unstructured":"Coppi, A. et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J. Exp. Med. 208, 341\u2013356 (2011).","journal-title":"J. Exp. Med."},{"key":"272_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.2409595","volume":"228","author":"F Zavala","year":"1985","unstructured":"Zavala, F. et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228, 1436\u20131440 (1985).","journal-title":"Science"},{"key":"272_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/328257a0","volume":"328","author":"DA Herrington","year":"1987","unstructured":"Herrington, D. A. et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328, 257\u2013259 (1987).","journal-title":"Nature"},{"key":"272_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(87)90540-X","volume":"1","author":"WR Ballou","year":"1987","unstructured":"Ballou, W. R. et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1, 1277\u20131281 (1987).","journal-title":"Lancet"},{"key":"272_CR15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4049\/jimmunol.140.2.626","volume":"140","author":"HM Etlinger","year":"1988","unstructured":"Etlinger, H. M. et al. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum. J. Immunol. 140, 626\u2013633 (1988).","journal-title":"J. Immunol."},{"key":"272_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1365-3024.1991.tb00272.x","volume":"13","author":"TR Burkot","year":"1991","unstructured":"Burkot, T. R., Da, Z. W., Geysen, H. M., Wirtz, R. A. & Saul, A. Fine specificities of monoclonal antibodies against the Plasmodium falciparum circumsporozoite protein: recognition of both repetitive and non-repetitive regions. Parasite Immunol. 13, 161\u2013170 (1991).","journal-title":"Parasite Immunol."},{"key":"272_CR17","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.4049\/jimmunol.169.12.6681","volume":"169","author":"C Persson","year":"2002","unstructured":"Persson, C. et al. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J. Immunol. 169, 6681\u20136685 (2002).","journal-title":"J. Immunol."},{"key":"272_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1084\/jem.156.1.20","volume":"156","author":"EH Nardin","year":"1982","unstructured":"Nardin, E. H. et al. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 156, 20\u201330 (1982).","journal-title":"J. Exp. Med"},{"key":"272_CR19","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/S0264-410X(97)00238-7","volume":"16","author":"EH Nardin","year":"1998","unstructured":"Nardin, E. H. et al. Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein. Vaccine 16, 590\u2013600 (1998).","journal-title":"Vaccine"},{"key":"272_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4049\/jimmunol.166.1.481","volume":"166","author":"EH Nardin","year":"2001","unstructured":"Nardin, E. H. et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 166, 481\u2013489 (2001).","journal-title":"J. Immunol."},{"key":"272_CR21","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1128\/IAI.59.8.2529-2534.1991","volume":"59","author":"ZM Khan","year":"1991","unstructured":"Khan, Z. M. & Vanderberg, J. P. Role of host cellular response in differential susceptibility of nonimmunized BALB\/c mice to Plasmodium berghei and Plasmodium yoelii sporozoites. Infect. Immun. 59, 2529\u20132534 (1991).","journal-title":"Infect. Immun."},{"key":"272_CR22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2307\/3283617","volume":"79","author":"JP Vanderberg","year":"1993","unstructured":"Vanderberg, J. P., Khan, Z. M. & Stewart, M. J. Induction of hepatic inflammatory response by Plasmodium berghei sporozoites protects BALB\/c mice against challenge with Plasmodium yoelii sporozoites. J. Parasitol. 79, 763\u2013767 (1993).","journal-title":"J. Parasitol."},{"key":"272_CR23","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White, M. T. et al. Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect. Dis. 15, 1450\u20131458 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"272_CR24","doi-asserted-by":"publisher","first-page":"6929","DOI":"10.1128\/IAI.01151-06","volume":"74","author":"JM Calvo-Calle","year":"2006","unstructured":"Calvo-Calle, J. M. et al. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge. Infect. Immun. 74, 6929\u20136939 (2006).","journal-title":"Infect. Immun."},{"key":"272_CR25","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(19)30937-7","volume":"393","author":"P Adepoju","year":"2019","unstructured":"Adepoju, P. RTS,S malaria vaccine pilots in three African countries. Lancet 393, 1685 (2019).","journal-title":"Lancet"},{"key":"272_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS S Clinical Trials Partnership.","year":"2015","unstructured":"RTS S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"272_CR27","first-page":"164","volume":"119","author":"RF Anders","year":"1986","unstructured":"Anders, R. F. et al. Antigenic repeat structures in proteins of Plasmodium falciparum. Ciba Found. Symp. 119, 164\u2013183 (1986).","journal-title":"Ciba Found. Symp."},{"key":"272_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.4513","volume":"24","author":"J Tan","year":"2018","unstructured":"Tan, J. et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24, 401\u2013407 (2018).","journal-title":"Nat. Med"},{"key":"272_CR29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408\u2013416 (2018).","journal-title":"Nat. Med."},{"key":"272_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/infdis\/jiv154","volume":"212","author":"DA Espinosa","year":"2015","unstructured":"Espinosa, D. A. et al. Proteolytic cleavage of the Plasmodium falciparum circumsporozoite protein is a target of protective antibodies. J. Infect. Dis. 212, 1111\u20131119 (2015).","journal-title":"J. Infect. Dis."},{"key":"272_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008373","volume":"16","author":"D Oyen","year":"2020","unstructured":"Oyen, D. et al. Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein. PLoS Pathog. 16, e1008373 (2020).","journal-title":"PLoS Pathog."},{"key":"272_CR32","doi-asserted-by":"publisher","unstructured":"Murugan, R. et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-020-0881-9 (2020).","DOI":"10.1038\/s41591-020-0881-9"},{"key":"272_CR33","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1126\/science.2480642","volume":"246","author":"EH Nardin","year":"1989","unstructured":"Nardin, E. H. et al. Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer. Science 246, 1603\u20131606 (1989).","journal-title":"Science"},{"key":"272_CR34","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/intimm\/3.10.997","volume":"3","author":"A Moreno","year":"1991","unstructured":"Moreno, A. et al. Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int. Immunol. 3, 997\u20131003 (1991).","journal-title":"Int. Immunol."},{"key":"272_CR35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4049\/jimmunol.151.1.489","volume":"151","author":"A Moreno","year":"1993","unstructured":"Moreno, A. et al. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J. Immunol. 151, 489\u2013499 (1993).","journal-title":"J. Immunol."},{"key":"272_CR36","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4049\/jimmunol.159.3.1362","volume":"159","author":"JM Calvo-Calle","year":"1997","unstructured":"Calvo-Calle, J. M. et al. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J. Immunol. 159, 1362\u20131373 (1997).","journal-title":"J. Immunol."},{"key":"272_CR37","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.4049\/jimmunol.137.9.2952","volume":"137","author":"G Del Giudice","year":"1986","unstructured":"Del Giudice, G. et al. The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines. J. Immunol. 137, 2952\u20132955 (1986).","journal-title":"J. Immunol."},{"key":"272_CR38","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1084\/jem.164.2.655","volume":"164","author":"MF Good","year":"1986","unstructured":"Good, M. F. et al. Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine. J. Exp. Med. 164, 655\u2013660 (1986).","journal-title":"J. Exp. Med"},{"key":"272_CR39","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/0264-410X(94)90337-9","volume":"12","author":"GA de Oliveira","year":"1994","unstructured":"de Oliveira, G. A., Clavijo, P., Nussenzweig, R. S. & Nardin, E. H. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application. Vaccine 12, 1012\u20131017 (1994).","journal-title":"Vaccine"},{"key":"272_CR40","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1128\/IAI.63.3.934-939.1995","volume":"63","author":"JA Stoute","year":"1995","unstructured":"Stoute, J. A. et al. Induction of humoral immune response against Plasmodium falciparum sporozoites by immunization with a synthetic peptide mimotope whose sequence was derived from screening a filamentous phage epitope library. Infect. Immun. 63, 934\u2013939 (1995).","journal-title":"Infect. Immun."},{"key":"272_CR41","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1006\/jmbi.2001.5258","volume":"315","author":"MC Bonaldo","year":"2002","unstructured":"Bonaldo, M. C. et al. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J. Mol. Biol. 315, 873\u2013885 (2002).","journal-title":"J. Mol. Biol."},{"key":"272_CR42","doi-asserted-by":"publisher","first-page":"12528","DOI":"10.1073\/pnas.1407362111","volume":"111","author":"C Deal","year":"2014","unstructured":"Deal, C. et al. Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice. Proc. Natl Acad. Sci. USA 111, 12528\u201312532 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"272_CR43","doi-asserted-by":"publisher","first-page":"E1922","DOI":"10.1073\/pnas.1207738109","volume":"109","author":"AT Isaacs","year":"2012","unstructured":"Isaacs, A. T. et al. Transgenic Anopheles stephensi coexpressing single-chain antibodies resist Plasmodium falciparum development. Proc. Natl Acad. Sci. USA 109, E1922\u2013E1930 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"272_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1126\/science.6985745","volume":"207","author":"N Yoshida","year":"1980","unstructured":"Yoshida, N., Nussenzweig, R. S., Potocnjak, P., Nussenzweig, V. & Aikawa, M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207, 71\u201373 (1980).","journal-title":"Science"},{"key":"272_CR45","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4049\/jimmunol.150.4.1403","volume":"150","author":"JM Calvo-Calle","year":"1993","unstructured":"Calvo-Calle, J. M. et al. Immunogenicity of multiple antigen peptides containing B and non-repeat T cell epitopes of the circumsporozoite protein of Plasmodium falciparum. J. Immunol. 150, 1403\u20131412 (1993).","journal-title":"J. Immunol."},{"key":"272_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jim.2004.06.017","volume":"292","author":"KA Kumar","year":"2004","unstructured":"Kumar, K. A., Oliveira, G. A., Edelman, R., Nardin, E. & Nussenzweig, V. Quantitative Plasmodium sporozoite neutralization assay (TSNA). J. Immunol. Methods 292, 157\u2013164 (2004).","journal-title":"J. Immunol. Methods"},{"key":"272_CR47","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1128\/IAI.00974-08","volume":"77","author":"C Othoro","year":"2009","unstructured":"Othoro, C. et al. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect. Immun. 77, 739\u2013748 (2009).","journal-title":"Infect. Immun."},{"key":"272_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/srep32575","volume":"6","author":"RA Mitchell","year":"2016","unstructured":"Mitchell, R. A., Altszuler, R., Frevert, U. & Nardin, E. H. Skin scarification with Plasmodium falciparum peptide vaccine using synthetic TLR agonists as adjuvants elicits malaria sporozoite neutralizing immunity. Sci. Rep. 6, 32575 (2016).","journal-title":"Sci. Rep."},{"key":"272_CR49","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0020-7519(01)00265-X","volume":"31","author":"O Bruna-Romero","year":"2001","unstructured":"Bruna-Romero, O. et al. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int. J. Parasitol. 31, 1499\u20131502 (2001).","journal-title":"Int. J. Parasitol."},{"key":"272_CR50","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/216160a0","volume":"216","author":"RS Nussenzweig","year":"1967","unstructured":"Nussenzweig, R. S., Vanderberg, J., Most, H. & Orton, C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216, 160\u2013162 (1967).","journal-title":"Nature"},{"key":"272_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4269\/ajtmh.1982.31.609","volume":"31","author":"LH Schmidt","year":"1982","unstructured":"Schmidt, L. H. Plasmodium cynomolgi infections in the rhesus monkey. Am. J. Trop. Med. Hyg. 31, 609\u2013611 (1982).","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00272-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00272-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00272-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T22:47:55Z","timestamp":1697582875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00272-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["272"],"URL":"https:\/\/doi.org\/10.1038\/s41541-020-00272-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]},"assertion":[{"value":"5 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}